<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Pharmaceuticals on WebNotes</title><link>https://v2.webnotes.in/tags/pharmaceuticals/</link><description>Recent content in Pharmaceuticals on WebNotes</description><generator>Hugo</generator><language>en-IN</language><lastBuildDate>Sat, 16 May 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://v2.webnotes.in/tags/pharmaceuticals/index.xml" rel="self" type="application/rss+xml"/><item><title>Cipla at PPFCF</title><link>https://v2.webnotes.in/cipla-at-ppfcf/</link><pubDate>Sat, 16 May 2026 00:00:00 +0000</pubDate><guid>https://v2.webnotes.in/cipla-at-ppfcf/</guid><description>&lt;h2 id="lead"&gt;Lead&lt;/h2&gt;
&lt;p&gt;&lt;a href="https://v2.webnotes.in/cipla-at-ppfcf/"&gt;Cipla Limited&lt;/a&gt;
 is among the periodic pharmaceutical holdings of the &lt;a href="https://v2.webnotes.in/parag-parikh-flexi-cap-fund/"&gt;Parag Parikh Flexi Cap Fund&lt;/a&gt;
 (PPFCF). The position has appeared in PPFCF factsheet portfolio listings across multiple cycles, alongside other healthcare holdings such as &lt;a href="https://v2.webnotes.in/ipca-laboratories-at-ppfcf/"&gt;IPCA Laboratories at PPFCF&lt;/a&gt;
.&lt;/p&gt;
&lt;p&gt;The Cipla thesis combines several elements of the broader &lt;a href="https://v2.webnotes.in/ppfas-investment-philosophy/"&gt;PPFAS investment philosophy&lt;/a&gt;
. First, respiratory-leadership: Cipla is among the global leaders in respiratory generics, with a deep portfolio of metered-dose inhalers, dry-powder inhalers and other delivery systems. Its respiratory franchise has been a key competitive advantage in both India and key export markets including South Africa, Europe and increasingly the United States. Second, US generics scale: Cipla has built a meaningful US business with a portfolio of complex generics including respiratory generics, peptides and other niche products. Third, disciplined valuation-driven entry: the team has typically built or added to the position during cyclical compression windows.&lt;/p&gt;</description></item><item><title>IPCA Laboratories at PPFCF</title><link>https://v2.webnotes.in/ipca-laboratories-at-ppfcf/</link><pubDate>Sat, 16 May 2026 00:00:00 +0000</pubDate><guid>https://v2.webnotes.in/ipca-laboratories-at-ppfcf/</guid><description>&lt;h2 id="lead"&gt;Lead&lt;/h2&gt;
&lt;p&gt;&lt;a href="https://v2.webnotes.in/ipca-laboratories-at-ppfcf/"&gt;IPCA Laboratories Limited&lt;/a&gt;
 is among the periodic pharmaceutical mid-cap holdings of the &lt;a href="https://v2.webnotes.in/parag-parikh-flexi-cap-fund/"&gt;Parag Parikh Flexi Cap Fund&lt;/a&gt;
 (PPFCF). The position has appeared in PPFCF factsheet portfolio listings across multiple cycles, alongside other healthcare holdings such as &lt;a href="https://v2.webnotes.in/cipla-at-ppfcf/"&gt;Cipla at PPFCF&lt;/a&gt;
.&lt;/p&gt;
&lt;p&gt;The IPCA Laboratories thesis combines several elements of the broader &lt;a href="https://v2.webnotes.in/ppfas-investment-philosophy/"&gt;PPFAS investment philosophy&lt;/a&gt;
. First, specialty therapy-area leadership: IPCA has historically been one of India&amp;rsquo;s largest manufacturers of anti-malarial active pharmaceutical ingredients (APIs) and formulations and has built strong franchises in cardiovascular, pain management and rheumatology. Second, generics and branded formulations mix: the company operates a balanced revenue mix across regulated-market generics exports, semi-regulated and emerging markets and Indian branded formulations. Third, disciplined valuation-driven entry: the team has typically built or added to the position during cyclical compression windows.&lt;/p&gt;</description></item></channel></rss>